Scarica l'app Stockscreener
54.28
1.93%
-1.07
Dopo l'orario di chiusura:
55.24
0.96
+1.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$55.35
Aprire:
$55.16
Volume 24 ore:
4.24M
Relative Volume:
1.17
Capitalizzazione di mercato:
$24.06B
Reddito:
$2.44B
Utile/perdita netta:
$1.36B
Rapporto P/E:
28.43
EPS:
1.9093
Flusso di cassa netto:
$574.14M
1 W Prestazione:
+1.08%
1M Prestazione:
-0.40%
6M Prestazione:
+38.29%
1 anno Prestazione:
+50.19%
Intervallo 1D:
$54.20
$55.57
Intervallo di 1 settimana:
$51.15
$55.57
Portata 52W:
$34.08
$56.50
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
54.28 | 24.54B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
475.20 | 118.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
623.43 | 64.79B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
852.50 | 53.07B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.06 | 38.48B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
169.77 | 36.04B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | UBS | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX) - Stock Titan
Kirr Marbach & Co. LLC IN Acquires Shares of 237,895 Royalty Pharma PLC $RPRX - MarketBeat
Form 144 Royalty Pharma PLC For: 23 June By Investing.com - Investing.com South Africa
[144] Royalty Pharma plc SEC Filing - Stock Titan
Look Beyond Market Euphoria After 3 FCF ETFs Rebalanced - ETF Database
Royalty Pharma plc (RPRX) Stock Analysis: Exploring an 11.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Three “Forever Stocks” for the AI Age - InvestorPlace
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dorsey Asset Management LLC Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Delta Global Management LP Acquires Shares of 44,314 Royalty Pharma PLC $RPRX - MarketBeat
[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report - Stock Titan
L2 Asset Management LLC Has $5.63 Million Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 31,091 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Yahoo Finance
Royalty Pharma PLC $RPRX Shares Bought by Entropy Technologies LP - MarketBeat
Royalty Pharma (RPRX) Stock Valuation After 11% Revenue Growth And US$1.25b In New Royalty Deals - Sahm
Fieldview Capital Management LLC Invests $3.74 Million in Royalty Pharma PLC $RPRX - MarketBeat
Eventide Asset Management LLC Raises Stake in Royalty Pharma PLC $RPRX - MarketBeat
Rhenman & Partners Asset Management AB Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
This Royalty Pharma Insider Reduced Their Stake By 10% - Yahoo Finance
Heartland Advisors Inc. Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
TD Asset Management Inc Has $9.19 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
CenterBook Partners LP Has $2.71 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Transcript : Royalty Pharma plc Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 04 - marketscreener.com
RPRX: Synthetic royalties and R&D partnerships drive growth, with China and large pharma as key opportunities - TradingView
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
RPRX Q1 2026 Earnings: EPS Surpasses Estimates by 5.11%, Stock SlipsEarnings Stability Report - newsline.com
Royalty Pharma (RPRX) director receives 4,545 share unit award - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant - Stock Titan
Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX) - Stock Titan
Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant - Stock Titan
Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares - Stock Titan
Royalty Pharma (RPRX) awards 4,545 RSUs to board director - Stock Titan
Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan - Stock Titan
Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares - Stock Titan
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week HighTime to Buy? - MarketBeat
Royalty Pharma (RPRX) Stock Analysis: Is the 6.05% Potential Upside Worth the Investment? - DirectorsTalk Interviews
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
5.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):